Found: 8
Select item for more details and to access through your institution.
Discovery of Rogaratinib (BAY 1163877): a pan‐FGFR Inhibitor.
- Published in:
- ChemMedChem, 2018, v. 13, n. 5, p. 437, doi. 10.1002/cmdc.201700718
- By:
- Publication type:
- Article
Enhanced internal dynamics of a membrane transport protein during substrate translocation.
- Published in:
- Protein Science: A Publication of the Protein Society, 2000, v. 9, n. 11, p. 2246
- By:
- Publication type:
- Article
Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice.
- Published in:
- European Journal of Medical Research, 2023, v. 28, n. 1, p. 1, doi. 10.1186/s40001-023-01099-2
- By:
- Publication type:
- Article
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
- Published in:
- Molecular Oncology, 2024, v. 18, n. 3, p. 726, doi. 10.1002/1878-0261.13577
- By:
- Publication type:
- Article
Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery.
- Published in:
- Scientific Reports, 2016, p. 28951, doi. 10.1038/srep28951
- By:
- Publication type:
- Article
Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models.
- Published in:
- Journal of Neurochemistry, 2017, v. 140, n. 1, p. 170, doi. 10.1111/jnc.13877
- By:
- Publication type:
- Article
Monitoring regulated protein-protein interactions using split TEV.
- Published in:
- Nature Methods, 2006, v. 3, n. 12, p. 985, doi. 10.1038/nmeth967
- By:
- Publication type:
- Article
Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models.
- Published in:
- International Journal of Cancer, 2019, v. 145, n. 5, p. 1346, doi. 10.1002/ijc.32224
- By:
- Publication type:
- Article